UBS O'Connor’s GoodRx Holdings GDRX Stock Holding History

UBS O'Connor’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-190,000	Closed	-$7.41M	–	900
2021 Q1	$7.41M	Buy	190,000 +15,000	+9%	+$675K	0.11%	130
2020 Q4	$7.06M	Buy	+175,000	New	+$8.04M	0.14%	138

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Atreides Management Boston, Massachusetts $5B AUM 78.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

UBS O'Connor's GDRX Position: Q2 2021 in Review

UBS O'Connor sold out of GoodRx Holdings (GDRX) in Q2 2021, closing a stake of 190,000 shares — an estimated $7.41M sold.

UBS O'Connor first reported a position in GDRX in Q4 2020 and held it in 2 quarters. The position peaked at $7.41M in Q1 2021. 199 funds tracked by Wall St. Rank hold GDRX as of Q2 2021.

UBS O'Connor reported no remaining GoodRx Holdings position as of Q2 2021 after selling out during the quarter.
UBS O'Connor sold 190,000 GoodRx Holdings shares in Q2 2021, an estimated $7.41M.
UBS O'Connor first reported a position in GoodRx Holdings in Q4 2020 and held it in 2 quarters.
UBS O'Connor's GoodRx Holdings position peaked at $7.41M in Q1 2021.
199 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2021.

Based on UBS O'Connor's 13F filing for Q2 2021, filed 13 Aug 2021.